![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
This review highlights advances made in cannabinoid chemistry over the time period August 2002 – June 2004. Particular emphasis is placed on new ligands for the CB1 and CB2 receptors. CB1 receptor antagonists have been a prominent area of research for many pharmaceutical companies. Sanofi’s CB1 receptor antagonist rimonabant has now generated clinical data demonstrating its efficacy for both obesity and smoking cessation in human subjects. Recent data showing the effects of CB2 agonists for pain in preclinical animal models has been accompanied by the reports from many laboratories disclosing selective CB2 agonists for the treatment of pain and other indications. The further progression of cannabinoid receptor agonists and antagonists into clinical trials will serve to determine the effectiveness of such compounds as therapeutics in the treatment of human diseases and disorders.